Dengue Vaccines, what is the situation in Jakarta?
What is the current status of dengue vaccine development?
There is a growing need for effective preventive interventions against dengue, a disease caused by four viruses, spread by mosquitos. One dengue vaccine has been licensed, Dengvaxia® , developed by Sanofi Pasteur.
What is Dengvaxia® ?
Dengvaxia is the first dengue vaccine to be licensed. It was first licensed in Mexico in December 2015 for use in individuals 9-45 years of age living in endemic areas. The vaccine is a live dengue vaccine developed by Sanofi Pasteur given as a series of 3 on a 0/6/12 month schedule.
The vaccine has been evaluated in two clinical trials (in five countries in Asia and in five countries in Latin America). Together, these trials included over 35,000 participants aged 2 to 16 years: ages at first vaccination were 2 to 14 years in one trial and 9 to 16 years in another.
WHO’s recommendations related to the Dengue vaccine
WHO recommends that countries should consider introduction of the dengue vaccine only in geographic settings where epidemiological data indicate a high burden of disease.
The vaccine is now available in Indonesia. The Indonesian national agency of drug and food control has licensed Dengvaxia for the use in children and young adolescents ( 9 to 16 years) ONLY. You may obtain a vaccination at our Good Practice clinic.